Rethinking HEOR Market Access Integration: A Ca...

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must o...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gr...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access